12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

MST-188 regulatory update

The European Commission granted Orphan Drug designation for Mast's MST-188 to treat sickle cell disease. Mast is evaluating MST-188 in the Phase III...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >